» Articles » PMID: 12680586

Expression and Function of the Ror-family Receptor Tyrosine Kinases During Development: Lessons from Genetic Analyses of Nematodes, Mice, and Humans

Overview
Publisher Informa Healthcare
Date 2003 Apr 12
PMID 12680586
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Receptor tyrosine kinases (RTKs) play crucial roles in various developmental processes. Ror-family RTKs are characterized by the intracellular tyrosine kinase domains, highly related to those of the Trk-family RTKs, and by the extracellular Frizzled-like cysteine-rich domains (CRDs) and Kringle domains. Rors are evolutionally conserved among Caenorhabditis elegans, Aplysia, Drosophila melanogaster, Xenopus, mice, and humans. In D. melanogaster and mammals, pairs of structurally related Rors are found, while a single Ror protein is identified in C. elegans or Aplysia. In Aplysia and D. melanogaster, Rors are expressed exclusively in developing nervous systems. On the other hand, rather widespread expression of Rors was observed in C. elegans and mammals. Mutations in Ror of C. elegans cause inappropriate axon outgrowth as well as defects in cell migration and asymmetric cell division. It has also been reported that the nematode Ror possesses kinase-dependent and kinase-independent functions. Mouse Rors, Ror1, and Ror2, are expressed mainly in migrating neural crest cells and mesenchymal cells, and Ror2-deficient mice exhibit skeletal abnormalities and ventricular septal defects in the heart. Although Ror1-deficient mice exhibit no apparent skeletal or cardiac abnormalities, Ror1/Ror2 double mutant mice show markedly enhanced skeletal and cardiac abnormalities compared with Ror2 mutant mice, indicating genetic interaction of Ror1 and Ror2. In humans, mutations within Ror2 have been found in two genetic skeletal disorders, recessive Robinow syndrome and dominant Brachydactyly type B (BDB), further emphasizing critical functions of Ror2 during developmental morphogenesis. In this article, we also discuss the signaling machinery mediated by Ror-family RTKs with a particular emphasis on our recent structure-function analyses of Ror-family RTKs.

Citing Articles

Integration of CD200, CD43 and ROR1 in Multiparameter Flow Cytometry (MFC) Routine Panels for the Differential Diagnosis of B-cell lymphoproliferative Disorders (B-LPDs).

Lagana A, Maglione R, Costa A, Mandelli B, Bisegna M, Milani M Mediterr J Hematol Infect Dis. 2025; 17(1):e2025002.

PMID: 39830795 PMC: 11740909. DOI: 10.4084/MJHID.2025.002.


Therapeutic advances in the targeting of ROR1 in hematological cancers.

Tigu A, Munteanu R, Moldovan C, Rares D, Kegyes D, Tomai R Cell Death Discov. 2024; 10(1):471.

PMID: 39551787 PMC: 11570672. DOI: 10.1038/s41420-024-02239-1.


Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?.

de Pellegars-Malhortie A, Picque Lasorsa L, Mazard T, Granier F, Prevostel C Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065798 PMC: 11279613. DOI: 10.3390/ph17070949.


Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 and in NB xenografts.

Chu Y, Nayyar G, Tian M, Lee D, Ozkaynak M, Ayala-Cuesta J Mol Ther Oncol. 2024; 32(2):200820.

PMID: 38933492 PMC: 11201149. DOI: 10.1016/j.omton.2024.200820.


A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells.

Ghaderi A, Okhovat M, Lehto J, De Petris L, Doulabi E, Kokhaei P Pharmaceutics. 2023; 15(4).

PMID: 37111634 PMC: 10145660. DOI: 10.3390/pharmaceutics15041148.